The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

advitos.com

Founded Year

2004

Stage

Private Equity | Alive

Total Raised

$24.35M

Last Raised

$24.35M | 1 yr ago

About ADVOS

ADVOS is a combined multi-organ support system for liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows both extracorporeal elimination of CO2, hepatic toxins, and water-soluble & protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS procedure works with dialysis-usual access and flow rates and does not require a gas exchanger for CO2 elimination.

ADVOS Headquarter Location

Agnes-Pockels-Bogen 1

Munich, 80992,

Germany

+49 89 411 18 42 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ADVOS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ADVOS is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,079 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

ADVOS Patents

ADVOS has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/6/2013

5/26/2015

Kidney diseases, Hepatology, Membrane technology, Blood, Fluid dynamics

Grant

Application Date

6/6/2013

Grant Date

5/26/2015

Title

Related Topics

Kidney diseases, Hepatology, Membrane technology, Blood, Fluid dynamics

Status

Grant

Latest ADVOS News

Personnel Boost in Effective Multi-Organ Support

Jan 28, 2022

) ADVITOS enjoys a well-earned reputation in the field of medical technology on the back of its self-developed ADVOS procedure – the 4-in-1 organ support for the treatment of multi-organ failure. The special properties along with the USPs of the ADVanced Organ Support (ADVOS) have been well received by its users in the medical community. The Munich-based scale-up has particularly enjoyed a healthy growth coupled with regular personnel acquisitions within the last decade. At the transition of 2021/2022, the team of experts in the field of multi-organ support is expanding once again. With three new additions in the medical management and sales and product management, ADVITOS continues on its path to further growth. Assoc.-Prof. Dr. Dr. Tobias Bingold has already taken up his position as Medical Director at ADVITOS in December 2021. At the beginning of 2022, the new Sales Director for the DACH region, Michael Spindeldreher, and the Product Manager, Thomas Lange, have also stepped into their roles. As of January 2022, the interdisciplinary team now comprises around 60 international specialists. Medical Director – Important Interface and Organization of Clinical Studies The position of the Medical Director is staffed by Assoc.-Prof. Dr. Dr. Tobias Bingold with his long-standing clinical experience, sound technical expertise and versatile competencies. The future development of ADVITOS finds invaluable assets with this key role and the expertise of Bingold. As Medical Director, Bingold forms a crucial interface between ADVITOS and the physicians in the hospitals. The focus of his activities lies on the planning and coordination of clinical studies. With Bingold, ADVITOS has gained more than 30 years of practical experience and solution-oriented expertise. Tobias Bingold brings Clinical Experience and Subject Matter Expertise to the Table As a link between the company and the hospitals and physicians, Bingold is likely to benefit from various stations in his career. As Managing Senior Physician for Intensive Care Medicine at Frankfurt University Hospital and as Clinic Director of the Clinic for Interdisciplinary Intensive Care Medicine and Intermediate Care at Helios Kliniken Wiesbaden (HSK) alone, Bingold can look back on more than ten years of experience in the medical management. The professional proximity to the core competence of ADVITOS, as well as to the field of application of the ADVOS procedure has also been provided. In addition to his various roles in anesthesiology, intensive care medicine and pain therapy, Bingold’s range of qualifications also includes a focus on infectious diseases. His multifaceted commitment is also reflected in his contribution to various medical publications, and in his membership in medical specialty societies. New Director in DACH Sales In the beginning of January, Michael Spindeldreher has also joined ADVITOS as Sales Director DACH. Spindeldreher takes up the sales activities entrusted to him in Germany, Austria and Switzerland not only with great experience and profound knowledge, but also out of genuine conviction and enthusiasm for the ADVOS therapy. Spindeldreher brings more than 15 years of professional experience to his new sales role, including former positions in customer service management, product management and international sales. His most recent role was that of Director of Sales at The Surgical Company since 2017. Here he succeeded to build a field sales team, and help the company become a market leader. Spindeldreher had already been eyeing the ADVITOS developmental endeavours with interest since 2019. He is convinced of the trend-setting idea, the innovative power, and effectiveness of the ADVOS therapy, and would like to actively contribute to its commercialization using his expertise from now on. Additional personnel also in sales, marketing, and product positioning The position of the new product manager has been filled by Thomas Lange since the beginning of January. With almost 30 years of practical experience and distinct competence in the field of medical technology, Lange’s ambition is to significantly expand the market share of the ADVOS therapy. Core competencies in sales and product management make Lange the ideal candidate for his position at ADVITOS, where he will be responsible for market-specific sales strategies, product-specific marketing plans and product positioning, amongst other things. This latest staff expansion by three established experts is a further sign of the determined course of ambition-fueled growth of ADVITOS. In 2022 and in the subsequent future, the company is looking forward to decisive developments in the market for medical products, which it intends to meet with motivation and drive, with expanded capacities and a high level of confidence. Tobias Bingold, Michael Spindeldreher, and Thomas Lange are convinced of the potential and effectiveness of the ADVOS therapy. As specialists experienced in medical technology, they are looking forward to making a sustainable contribution to its development and establishment. Pressemitteilung teilen:

ADVOS Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ADVOS Rank

  • When was ADVOS founded?

    ADVOS was founded in 2004.

  • Where is ADVOS's headquarters?

    ADVOS's headquarters is located at Agnes-Pockels-Bogen 1, Munich.

  • What is ADVOS's latest funding round?

    ADVOS's latest funding round is Private Equity.

  • How much did ADVOS raise?

    ADVOS raised a total of $24.35M.

  • Who are ADVOS's competitors?

    Competitors of ADVOS include Aethlon Medical, HistoSonics, Promedtek, eNeura Therapeutics, Game Ready and 14 more.

You May Also Like

P
Paragon Intellectual Properties

Nexeon MedSystems is committed to improving lives through the development of therapies for people with cardiovascular disease. With proven medical device research and development talent, a strong intellectual property portfolio and the leadership of a veteran interventional cardiologist, Nexeon has created an pipeline of products for unmet clinical needs.

T
ThermalTherapeutic Systems

ThermalTherapeutic Systems is currently developing a portable next-generation perfusion device for international distribution.

C
CardioGenesis

Cardiogenesis is a medical device company committed to innovating tools for the treatment of cardiovascular disease. The company, located in Orange County, California, is a provider in laser revascularization and angiogenic therapies for the treatment of severe angina.

F
Fairway Medical Technologies

Fairway Medical Technologies is an FDA registered medical device, design, development and manufacturing company. It invents, innovates, and invests in medical technologies. In addition to supporting early stage startups with technology and business development, Fairway helps them obtain SBIR (Small Business Innovative Research) and other commercialization grants. As of 2009, Fairway and its Portfolio Companies have received over $15 Million in grants from the National Institute of Health (NIH) and the State of Texas' Emerging Technology Fund (ETF).

E
Emergent Respiratory Products

Emergent Respiratory Products, Inc., located in Irvine, CA, aims to develop, manufacture and market a medical device for delivering non-invasive ventilation therapy. Emergent's products can be utilized in a range of care settings, including emergency medical service (EMS) transport to the hospital and alternative site/home care settings.

Promedtek Logo
Promedtek

ProMedTek is developing Composite Therapy for problem wounds in the medical device technology market.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.